IP Library Granted Patent US 8,252,808
Granted Patent B2
US 8,252,808 · App. 12/316,862 · Granted Aug 28, 2012

Process and compounds for the production of (+)opiates

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,252,808
App. No.
12/316,862
Granted
Aug 28, 2012
Kind
B2
Abstract

The invention generally provides processes and intermediate compounds useful for the production of (+)-opiates. Non-limiting examples of (+) opiates that may be derived from one or more compounds of the invention include (+)-noroxymorphone, (+)-naltrexone, (+)-naloxone, (+)-N-cyclopropylmethylnorhydrocodone, (+)-N-cycloproylmethylnorhydromorphone, (+)-N-allylnorhydrocodone, (+)-N-allylnorhydromorphone, (+)-noroxycodone, (+)-naltrexol, (+)-naloxol, and (+)-3-O-methyl-naltrexone.

Claims (43)

1. A compound having a formula (Ia):

wherein:

R 3 is selected from the group consisting of hydrogen, {−}C(O)R 6 , and {−}R 6 ;

R 5 is selected from the group consisting of alkyl having from 1 to 8 carbons, CH 3 CHCl—{−} and CH 2 ═CH—{−};

R 6 is selected from the group consisting of hydrocarbyl and hydrocarbyl substituted with at least one atom other than carbon;

R 8 and R 9 are independently selected from the group consisting of hydrogen, hydroxyl, hydrocarbyl, and hydrocarbyl substituted with at least one atom other than carbon, or R 8 and R 9 together form a carbonyl group;

R 12 and R 13 are independently selected from the group consisting of hydrogen, hydrocarbyl, and hydrocarbyl substituted with at least one atom other than carbon, or R 12 and R 13 together form a carbonyl group; and

R 10 , R 11 , and R 14 are independently selected from the group consisting of hydrogen, hydrocarbyl, hydrocarbyl substituted with at least one atom other than carbon, and a halogen.

2. A compound having a formula (Ib):

wherein:

R 1 is selected from the group consisting of hydrogen, and {−}C(O)R 5 ;

R 3 is selected from the group consisting of hydrogen, {−}C(O)R 6 , and {−}R 6 ;

R 5 and R 5 are independently selected from the group consisting of hydrocarbyl and hydrocarbyl substituted with at least one atom other than carbon;

R 8 and R 9 are independently selected from the group consisting of hydrogen, hydroxyl, hydrocarbyl, and hydrocarbyl substituted with at least one atom other than carbon, or R 8 and R 9 together form a carbonyl group;

R 12 and R 13 are independently selected from the group consisting of hydrogen, hydrocarbyl, and hydrocarbyl substituted with at least one atom other than carbon, or R 12 and R 13 together form a carbonyl group; and

R 10 , R 11 , R 14 and R 15 are independently selected from the group consisting of hydrogen, hydrocarbyl, hydrocarbyl substituted with at least one atom other than carbon, and a halogen, or R 14 and R 15 together form a carbonyl group.

3. A process for the preparation of compound (Ib) according to the following reaction scheme:

wherein:

R is selected from hydrocarbyl, and hydrocarbyl substituted with at least one atom other than carbon;

R 1 is selected from the group consisting of hydrogen and {−}C(O)R 5 ;

R 3 is selected from the group consisting of hydrogen, {−}C(O)R 6 , and {−}R 6 ;

R 5 and R 6 are independently selected from the group consisting of hydrocarbyl and hydrocarbyl substituted with at least one atom other than carbon;

R 8 and R 9 are independently selected from the group consisting of hydrogen, hydroxyl, hydrocarbyl, and hydrocarbyl substituted with at least one atom other than carbon, or R 8 and R 9 together form a carbonyl group;

R 12 , and R 13 are independently selected from the group consisting of hydrogen, hydrocarbyl, and hydrocarbyl substituted with at least one atom other than carbon, or R 12 and R 13 together form a carbonyl group;

R 10 , R 11 , and R 14 are independently selected from the group consisting of hydrogen, hydrocarbyl, hydrocarbyl substituted with at least one atom other than carbon, and a halogen;

R 15 is hydrogen; and

X is a halogen.

4. The process of claim 3 , wherein R, R 5 and R 6 are independently selected from the group consisting of an alkyl group having from 1 to 8 carbon atoms, an aryl group, CH 3 CHCl—{−}, and an {−}CH 2 -aryl group, and X is chlorine.

5. The process of claim 3 , the molar ratio of the compound comprising formula (II) to ROCOX to proton acceptor is from about 1:3:1 to about 1:12:12; the proton acceptor is a salt with a pH greater than 7; the reaction of Step A is conducted in the presence of an aprotic solvent; and at a temperature ranging from about 45° C. to about 120° C.; the molar ratio of compound (Ia) to transition metal catalyst is from about 1:0.0005 to about 1:0.005, the reaction of Step B is conducted under pressurized hydrogen having a pressure from about 0 to about 500 PSI, the reaction of Step B is conducted in the presence of a methanol-containing solvent, and at a temperature ranging from about 20° C. to about 120° C.

6. A process for the preparation of compound (Ib) according to the following reaction scheme:

wherein:

R is selected from hydrocarbyl, and hydrocarbyl substituted with at least one atom other than carbon;

R 1 is selected from the group consisting of hydrogen and {−}C(O)R 5 ;

R 3 is selected from the group consisting of hydrogen, {−}C(O)R 6 , and {−}R 6 ;

R 5 and R 6 are independently selected from the group consisting of hydrocarbyl and hydrocarbyl substituted with at least one atom other than carbon;

R 8 and R 9 are independently selected from the group consisting of hydrogen, hydroxyl, hydrocarbyl, and hydrocarbyl substituted with at least one atom other than carbon, or R 8 and R 9 together form a carbonyl group;

R 12 , and R 13 are independently selected from the group consisting of hydrogen, hydrocarbyl, and hydrocarbyl substituted with at least one atom other than carbon, or R 12 and R 13 together form a carbonyl group;

R 10 , R 11 , and R 14 are independently selected from the group consisting of hydrogen, hydrocarbyl, hydrocarbyl substituted with at least one atom other than carbon, and a halogen;

R 15 is hydrogen; and

X is a halogen.

7. The process of claim 6 , wherein R, R 5 and R 6 are independently selected from the group consisting of an alkyl group having from 1 to 8 carbon atoms, an aryl group, CH 3 CHCl—{−}, CH 2 ═CH—{−}, and an {−}CH 2 -aryl group, and X is chlorine.

8. The process of claim 6 , wherein the molar ratio of the compound comprising formula (II) to proton donor to transition metal catalyst is from about 1:0.5:0.0005 to about 1:10:0.05, the of reaction of Step A is conducted under pressurized hydrogen having a pressure from about 0 to about 500 PSI, the reaction of Step A is conducted in the presence of a methanol-containing solvent, and the at a temperature ranging from about 20° C. to about 120° C.; the molar ratio of the compound comprising formula (IIa) to ROCOX to proton acceptor is from about 1:2:1 to about 1:20:20, the reaction of Step B is conducted in the presence of an aprotic solvent, and at a temperature ranging from about 45° C. to about 120° C.

9. The process of claim 8 , wherein the proton donor is selected from the group consisting of HOAc, HCO 2 H, HCl, and H 2 SO 4 ; the transition metal catalyst is selected from the group consisting of Pd/C, Pt/C, Ru/C, and Rh/C; and the proton acceptor is selected from the group consisting of NaHCO 3 , KHCO 3 , LiHCO 3 , Na 2 CO 3 , K 2 CO 3 , Li 2 CO 3 , and combinations thereof.

Assignments (14)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 31, 2025
From: SPECGX LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 072313/0063 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2017
From: MALLINCKRODT LLC
To: SPECGX LLC
Reel/Frame 044891/0376 →
SECURITY INTEREST Recorded Mar 19, 2014
From: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS INC.; MALLINCKRODT CARIBBEAN, INC.; MALLINCKRODT US POOL LLC; MALLINCKRODT INC.; LUDLOW CORPORATION; CNS THERAPEUTICS, INC.; ENTERPRISES HOLDINGS, INC.; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS, INC; MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC; MALLINCKRODT ENTERPRISES HOLDINGS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 032480/0001 →
CHANGE OF LEGAL ENTITY Recorded Aug 16, 2011
From: MALLINCKRODT INC.
To: MALLINCKRODT LLC
Reel/Frame 026754/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 2, 2009
From: WANG, PETER X.; JIANG, TAO; CANTRELL, GARY L.; BERBERICH, DAVID W.; TRAWICK, BOBBY N.; OSIEK, TODD; LIAO, SUBO; MOSER, FRANK W.; MCCLURG, JOSEPH P.
To: MALLINCKRODT INC.
Reel/Frame 022188/0941 →